72% of NSCLC Patients with MET Mutation Respond to Capmatinib

By Annette M. Boyle /alert Contributor
Save to PDF By

Patients with non-small cell lung cancer with the METΔex14 mutation may have a new option for treatment, if additional research supports results presented at the European Society for Medical Oncology  (ESMO) 2018 Congress in Munich, Germany in October.

The Phase II GEOMETRY mono-1 study found that nearly three-quarters of treatment-naïve patients responded to capmatinib, a selective MET inhibitor. Previously treated patients also responded, but at a reduced rate.

Photo Courtesy of ESMO

All patients in the study had stage IIIB/IV NSCLC with the METΔex14 and wild-type ALK and EGFR. Patients with this profile currently constitute a “challenging patient population,” according to the presenter, Juergen Wolf, MD, of the Centre for Integrated Oncology at the University Hospital Cologne in Cologne, Germany.

Participants received 400 mg of capmatinib twice a day.

After a follow-up period of at least 18 weeks, 72% of treatment-naïve patients and 39.1% of previously treated patients demonstrated response. At the time of the data closure, 44% of treatment-naïve patients continued to receive treatment as did 20.3% of those who had previously been treated. With a median follow up of 5.6 months, the researchers noted that duration of response data had not matured.

The investigators also reported preliminary activity in patients with brain metastases.

While the response rate was calculated for just two arms of the GEOMETRY trial, the research team reported safety results from all six arms. The most common adverse events of any grade were peripheral edema (49%), nausea (43.4%), vomiting (28.5%), blood creatinine increase (24.5%) and dyspnea (24.2%).

The investigators noted that the significant difference in response rates between those who received capmatinib in the first versus subsequent lines highlights the need for earlier diagnostic testing to enable prompt first-line treatment with capmatinib for patients with the METΔex14 mutation.

LBA52 – Wolf J, Seto T, Han J-Y, et al. Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14mutated advanced non-small cell lung cancer (NSCLC).